Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Strides Shasun not...

    Strides Shasun not impacted by WHO Notice

    Written by savita thakur thakur Published On 2016-04-27T09:24:38+05:30  |  Updated On 27 April 2016 9:24 AM IST

    New Delhi : Pharma firm Strides Shasun said its business will not be impacted by WHO strictures on drugs approved on the basis of studies by Bangalore-based Semler Research Center due to data integrity issues as its two TB medicines have already been discontinued.


    In a notice of concern issued by the WHO to the Bangalore based Semler on April 12, two pre-qualified products of Strides Shasun were also mentioned, it said in a BSE filing.


    "There will not be any impact on the company's business as the two tuberculosis products mentioned in the notice of concern pertaining to our institutional business have been discontinued since mid-2014," it added.


    Strides Shasun's isoniazid/rifampicin 75mg/150mg and ethambutol HCL/Isoniazid/pyrazinamide/rifampicin 275 mg were in the list of drugs over which the World Health Organisation (WHO) raised questions to the validity of studies performed by Semler.


    WHO had issued the notice to Semler citing data integrity issues and pulled up the contract research firm stating there were at manipulation of at least five studies over an extended period of time indicating it is a common practice.


    The global body had asked companies whose products are in its pre-qualified list to carry out risk assessments with proposed corrective and preventive and submit all the studies within 30 days.


    Earlier last week, USFDA had told drug firms that their applications seeking approvals on the basis of studies done by Semler would not be accepted citing data integrity issues.


    Strides Shasun stock was trading at Rs 1,123.20, up 2.09 per cent, in the afternoon of BSE.

    HCLIsoniazidPyrazinamiderifampicinStrides ShasunTB medicinesUS Food & Drug AdministrationUSFDAWHOWorld Health Organisation
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok